CAR-T and Cell Therapy: Reimbursement and Treatment-Slot Capacity | Oncology Modality Intelligence

Description

List of Tables

Japan was early to reimburse CAR-T therapy - Kymriah entered the NHI schedule in 2019, followed by Yescarta, Breyanzi, Tecartus, Abecma, and Carvykti - and then built one of the most controlled delivery systems in the world around it. Treatment is confined to certified centers that meet standards set jointly by the transplant and cell-therapy societies, and every eligible patient moves through a fixed chain: referral, slot allocation, apheresis, manufacturing, bridging therapy, infusion, and monitored recovery. The result is a market where demand is not the limiting variable; capacity is, and almost none of the system's utilization data is available in English.

The tension is structural. Certified centers are large academic hospitals with competing demands on beds, ICU access, and cell-processing staff, so treatment slots grow slowly even as labels expand into earlier lines and new myeloma indications. Manufacturers face a chicken-and-egg problem: investing in Japanese vein-to-vein infrastructure only pays if slots exist, and slots only grow if volume justifies hospital investment. Meanwhile the arrival of off-the-shelf bispecifics gives physicians an alternative that bypasses the queue entirely, and domestic players - Takara Bio with its own CD19 program and CDMO operations, Terumo and Miltenyi in apheresis and processing hardware - are positioning for a version of the market that may localize manufacturing. How reimbursement rules, certification standards, and competitive pressure interact to set the slot count is the report's central question.

This report reconstructs the Japanese CAR-T channel end to end. It details each reimbursed product's label, price, and certification footprint; explains the society certification regime and slot-allocation mechanics; models center economics under NHI fees; and profiles the manufacturing, logistics, and equipment layers that determine how quickly capacity can form. Chapters also cover the bispecific substitution threat, domestic cell-therapy development, and the China CAR-T context through Fosun Kite, JW Therapeutics, and IASO.

The report serves cell-therapy companies planning Japanese manufacturing or launch, CDMOs and equipment suppliers, hospital strategists, and investors. It provides the operational detail - certification requirements, slot mechanics, cost structures - that headline market figures leave out.

Scope and Coverage: The report covers CD19 and BCMA CAR-T products reimbursed in Japan, the certified-center system, reimbursement mechanics, manufacturing and logistics infrastructure, and domestic development programs. It profiles Novartis, Kite/Gilead, Bristol Myers Squibb, Johnson & Johnson/Legend, Takara Bio, Terumo, Miltenyi, Autolus, and Chinese CAR-T developers, and analyzes bispecific competition for the same patients.

Report Highlights:

Details each reimbursed CAR-T product's Japanese label, NHI status, and certification footprint
Explains the society certification regime and treatment-slot allocation mechanics
Models certified-center economics under NHI fees and competing bed demands
Profiles Takara Bio's domestic program and Terumo/Miltenyi infrastructure roles
Analyzes bispecific substitution pressure on the CAR-T channel
Covers China CAR-T context via Fosun Kite, JW Therapeutics, and IASO Biotherapeutics

Product Code: JPH-030

Table of Content

1. Executive Summary

2. CAR-T and Cell Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

Novartis (CH) - Kymriah CD19 CAR-T; first reimbursed CAR-T in Japan
Gilead Sciences/Kite (US) - Yescarta and Tecartus CAR-T products
Bristol Myers Squibb (US) - Breyanzi and Abecma CAR-T products
Johnson & Johnson/Legend (US/CN) - Carvykti BCMA CAR-T
Takara Bio (JP) - domestic CD19 CAR-T developer and cell-therapy CDMO
Terumo (JP) - apheresis and cell-processing systems for cell-therapy centers
Miltenyi Biotec (DE) - cell-processing equipment supplier for CAR-T manufacturing
Autolus (UK) - Aucatzyl CD19 CAR-T
JW Therapeutics (CN) - Carteyva CD19 CAR-T in China
IASO Biotherapeutics (CN) - equecabtagene BCMA CAR-T in China
Fosun Kite (CN) - Yescarta China joint venture

Product Code: JPH-030

List of Tables

Table 1. CAR-T Mechanism and Product Architecture: CD19 and BCMA Classes
Table 2. Kymriah (Tisagenlecleucel): Japanese Labels and Reimbursement History
Table 3. Yescarta (Axicabtagene Ciloleucel): Japanese Labels and Center Footprint
Table 4. Breyanzi (Lisocabtagene Maraleucel): Japanese Labels and Differentiation Features
Table 5. Tecartus (Brexucabtagene Autoleucel): Mantle Cell and ALL Positioning in Japan
Table 6. Abecma (Idecabtagene Vicleucel): Myeloma Entry into the Japanese Channel
Table 7. Carvykti (Ciltacabtagene Autoleucel): Program Profile and Japan Status
Table 8. Pivotal Trial Programs Behind Japanese CAR-T Labels: ZUMA, JULIET, TRANSFORM, and KarMMa
Table 9. Certified-Center Regime: Society Standards and Certification Process
Table 10. Certification Requirements: Facilities, Staffing, and ICU Access
Table 11. Treatment-Slot Allocation Mechanics Within Certified Centers
Table 12. Vein-to-Vein Timeline: Referral, Apheresis, Manufacturing, and Infusion
Table 13. Bridging Therapy Practices While Awaiting Manufacturing
Table 14. CRS and ICANS Management Infrastructure at Certified Centers
Table 15. Long-Term Follow-Up Obligations for CAR-T Recipients in Japan
Table 16. NHI Pricing of CAR-T Products and the Cost-Effectiveness System
Table 17. CAR-T Pricing Precedents and Subsequent Revisions
Table 18. Center Economics: Revenue Components and Cost Drivers per Treatment Episode
Table 19. Referral Network Design from Community Hematology to Certified Centers
Table 20. Patient Eligibility Assessment and Multidisciplinary Review Process
Table 21. Geographic Distribution of Certified Centers and Access Gaps
Table 22. Novartis Manufacturing and Logistics Structure for Japan
Table 23. Kite/Gilead Supply-Chain Arrangements for the Japanese Market
Table 24. Bristol Myers Squibb Manufacturing Strategy for Breyanzi and Abecma
Table 25. Johnson & Johnson/Legend Carvykti Supply Considerations
Table 26. Takara Bio Domestic CD19 CAR-T Program and CDMO Operations
Table 27. Terumo Apheresis and Cell-Processing Systems in the CAR-T Chain
Table 28. Miltenyi Biotec Cell-Processing Equipment Roles
Table 29. Autolus Aucatzyl Program and Japan Relevance
Table 30. Fosun Kite Yescarta China Joint Venture: Structure and Lessons
Table 31. JW Therapeutics Carteyva and China CAR-T Commercialization Context
Table 32. IASO Biotherapeutics Equecabtagene and China BCMA Context
Table 33. Domestic Academic Cell-Therapy Programs in Japan
Table 34. Regenerative-Medicine Regulatory Framework: PMD Act Provisions for Cell Therapy
Table 35. Bispecific Antibody Substitution Pressure on CAR-T Referrals
Table 36. Earlier-Line Label Expansions and Their Slot-Demand Implications
Table 37. Outpatient and Community Administration Experiments Abroad: Lessons for Japan
Table 38. In-Vivo CAR-T and Next-Generation Concepts: Horizon Scan
Table 39. Solid-Tumor Cell-Therapy Programs and Japanese Trial Activity
Table 40. Slot-Capacity Formation Scenarios: Certification, Staffing, and Demand Paths
Table 41. Risk Register: Manufacturing Failures, Safety Events, and Channel Substitution
Table 42. Indicator Dashboard for CAR-T Channel Monitoring
Table 43. Due-Diligence Checklist for Cell-Therapy Infrastructure Investment
Table 44. Hospital Decision Framework for Seeking Certification
Table 45. Stakeholder Position Map: Societies, Payers, Manufacturers, and Centers
Table 46. Real-World Data Collection Systems for CAR-T in Japan
Table 47. Patient Assistance and Out-of-Pocket Structure for CAR-T Episodes
Table 48. Workforce Requirements: Cell-Processing Staff and Physician Training
Table 49. Cross-Border Manufacturing Options for Japanese Patients
Table 50. Analytical Appendix: Certification Lists, NHI Documents, and Registry Sources

List of Figures

Figure 1. CAR-T Mechanism and Product Class Map
Figure 2. Japanese CAR-T Product Timeline: Approvals and Listings
Figure 3. Label Map by Indication Across CD19 and BCMA Products
Figure 4. Pivotal Trial Program Map Behind Japanese Labels
Figure 5. Certified-Center Regime: Society Roles and Certification Flow
Figure 6. Certification Requirement Checklist Diagram
Figure 7. Treatment-Slot Allocation Flow Within a Certified Center
Figure 8. Vein-to-Vein Patient Journey Timeline
Figure 9. Bridging Therapy Decision Framework
Figure 10. CRS and ICANS Management Protocol Flow
Figure 11. Long-Term Follow-Up Obligation Map
Figure 12. NHI Pricing Pathway for Cell Therapies
Figure 13. Center Economics Waterfall per Treatment Episode
Figure 14. Referral Network Diagram from Community Hematology
Figure 15. Eligibility Assessment and Review Board Flow
Figure 16. Geographic Access Map Framework for Certified Centers
Figure 17. Novartis Japan Manufacturing and Logistics Diagram
Figure 18. Kite/Gilead Supply-Chain Structure for Japan
Figure 19. BMS Manufacturing Strategy Diagram
Figure 20. Carvykti Supply Consideration Map
Figure 21. Takara Bio Program and CDMO Structure
Figure 22. Terumo and Miltenyi Equipment Positions in the Chain
Figure 23. China CAR-T Context: Fosun Kite, JW, and IASO
Figure 24. Domestic Academic Cell-Therapy Program Map
Figure 25. PMD Act Regulatory Pathway for Cell Therapies
Figure 26. Bispecific Substitution Pressure Diagram
Figure 27. Earlier-Line Expansion Impact on Slot Demand
Figure 28. Outpatient Administration Models Abroad
Figure 29. In-Vivo CAR-T Concept Diagram
Figure 30. Solid-Tumor Cell-Therapy Trial Map in Japan
Figure 31. Slot-Capacity Scenario Tree
Figure 32. Risk Map: Manufacturing, Safety, and Substitution
Figure 33. CAR-T Channel Monitoring Dashboard
Figure 34. Infrastructure Investment Due-Diligence Flow
Figure 35. Hospital Certification Decision Tree
Figure 36. Stakeholder Position Map
Figure 37. Real-World Data Collection Architecture
Figure 38. Patient Cost Structure for a CAR-T Episode
Figure 39. Workforce Training Pathway for Cell-Therapy Staff
Figure 40. Cross-Border Manufacturing Option Map
Figure 41. Capacity Bottleneck Identification Framework
Figure 42. Apheresis Scheduling and Logistics Diagram
Figure 43. Manufacturer-Center Contract Structures
Figure 44. Quality Release Testing Flow for Autologous Products
Figure 45. Competitive Positioning Map Among Reimbursed Products
Figure 46. Hematology Department Referral Behavior Framework
Figure 47. Investor KPI Dashboard for the Japan CAR-T Theme
Figure 48. Sponsor Options for Localizing Manufacturing
Figure 49. Synthesis: Conditions for CAR-T Capacity Growth in Japan
Figure 50. Report Roadmap: Chapter Linkages to Reader Decisions

CAR-T and Cell Therapy: Reimbursement and Treatment-Slot Capacity | Oncology Modality Intelligence | US, EU5, Japan & China

Description

Table of Contents

List of Tables

Table of Content

1. Executive Summary

2. CAR-T and Cell Therapy: Modality Overview and Mechanism Landscape

3. Global Pipeline and Deal Activity

4. Key Programs, Clinical Readouts, and Evidence Status

5. Japan Relevance: Trials, Approvals, and Partnerships

6. Regulatory and Pricing Considerations in Japan

7. Competitive Positioning and Valuation Considerations

8. Watch Items and Upcoming Catalysts

9. Appendix: Methodology and Sources

Companies Mentioned

List of Tables

List of Figures